Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/15/2021 10/18/2021 10/19/2021 10/20/2021 10/21/2021 Date
109.33(c) 107.43(c) 107.45(c) 108.41(c) 108.2 Last
4 634 513 7 949 357 4 614 876 5 627 072 2 765 768 Volume
+0.39% -1.74% +0.02% +0.89% -0.19% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 56 197 M - -
Net income 2021 12 472 M - -
Net Debt 2021 66 426 M - -
P/E ratio 2021 14,8x
Yield 2021 4,79%
Sales 2022 59 549 M - -
Net income 2022 15 047 M - -
Net Debt 2022 53 623 M - -
P/E ratio 2022 12,0x
Yield 2022 5,16%
Capitalization 192 B 192 B -
EV / Sales 2021 4,59x
EV / Sales 2022 4,12x
Nbr of Employees 48 000
Free-Float 98,0%
More Financials
Company
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human... 
Sector
Pharmaceuticals
Calendar
10/29Earnings Release
More about the company
Ratings of AbbVie Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ABBVIE INC.
06:19aASTRAZENECA : Puts Cancer Drug Trial On Hold Due To Safety Concerns
MT
10/18ABBVIE : Receives CHMP Positive Opinion for Risankizumab (SKYRIZI) for the Treatment of Ad..
AQ
10/18OYSTER POINT PHARMA : drug becomes first FDA-approved nasal spray to treat dry eyes
RE
10/15REVANCE THERAPEUTICS : U.S. FDA declines to approve Revance's frown-line treatment
RE
10/15ABBVIE : Says its Psoriatic Arthritis Drug Risankizumab Recommended by CHMP for Treatment ..
MT
10/15AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of ..
CI
10/15AbbVie Gets CHMP Positive Opinion for Risankizumab in Psoriatic Arthritis
DJ
10/14PRESS RELEASE : Roche's Gazyvaro shorter 90-minute infusion time approved in Europe for pe..
DJ
10/14ABBVIE INC. : Ex-dividend day for
FA
10/12ABBVIE : Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Aware..
AQ
10/11Health Care Stocks Sliding in Late Monday Trading
MT
10/11Health Care Stocks Drifting Monday as Biotechs Climb
MT
10/08ABBVIE : Upadacitinib (RINVOQ) Met Primary and Most Ranked Secondary Endpoints in Phase 3 ..
AQ
10/08ABBVIE : RINVOQ (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 S..
AQ
10/07ABBVIE : Gets Health Canada's Approval for Rinvoq to Treat Atopic Dermatitis
MT
More news
News in other languages on ABBVIE INC.
06:19aAstraZeneca suspend l'essai d'un médicament contre le cancer en raison de problèmes de ..
10/11Les actions du secteur de la santé en baisse lundi en fin de journée
10/11Les actions du secteur de la santé à la dérive lundi alors que les biotechnologies grim..
10/07AbbVie obtient l'approbation de Santé Canada pour le traitement de la dermatite atopiqu..
10/07L'essai de phase 3 d'AbbVie sur l'upadacitinib pour le traitement potentiel des maux de..
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | ABBV | US00287Y1091 | MarketScreener
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 108,41 $
Average target price 125,48 $
Spread / Average Target 15,7%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.1.18%191 579
JOHNSON & JOHNSON4.07%431 148
ROCHE HOLDING AG13.98%333 101
PFIZER, INC.14.34%239 966
NOVO NORDISK A/S56.26%238 738
ELI LILLY AND COMPANY44.35%220 952